These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38457360)

  • 1. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
    Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
    Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells, particularly activated CD4
    Wang Z; Chimenti MS; Strouse C; Weiner GJ
    Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity.
    Wang Z; Yin C; Lum LG; Simons A; Weiner GJ
    J Hematol Oncol; 2021 Dec; 14(1):204. PubMed ID: 34886888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
    Beum PV; Lindorfer MA; Taylor RP
    J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
    Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
    Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
    Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK Cell Degranulation Triggered by Rituximab Identifies Potential Markers of Subpopulations with Enhanced Cytotoxicity toward Malignant B Cells.
    Wlodarczyk M; Torun A; Zerrouqi A; Pyrzynska B
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells
    Niu C; Chen Y; Li M; Zhu S; Zhou L; Xu D; Li Z; Xu J; Li W; Wang Y; Cui J
    Front Immunol; 2021; 12():658562. PubMed ID: 34113342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
    Wang SY; Racila E; Taylor RP; Weiner GJ
    Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
    Hassenrück F; Knödgen E; Göckeritz E; Midda SH; Vondey V; Neumann L; Herter S; Klein C; Hallek M; Krause G
    Biomed Res Int; 2018; 2018():1023490. PubMed ID: 29750146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
    Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
    J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.